Equities research analysts predict that Biopharmx Corp (NYSE:BPMX) will post sales of $20,000.00 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Biopharmx Corp’s earnings, with estimates ranging from $10,000.00 to $30,000.00. Biopharmx Corp also posted sales of $20,000.00 in the same quarter last year. The firm is scheduled to announce its next quarterly earnings results on Monday, September 11th.

On average, analysts expect that Biopharmx Corp will report full year sales of $20,000.00 for the current year, with estimates ranging from $30,000.00 to $590,000.00. For the next year, analysts anticipate that the business will post sales of $5.07 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Biopharmx Corp.

Separately, ValuEngine upgraded shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 24th.

Shares of Biopharmx Corp (BPMX) traded up 1.819% during midday trading on Wednesday, hitting $0.459. 320,493 shares of the stock traded hands. The stock’s market capitalization is $34.03 million. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $1.22. The firm has a 50-day moving average price of $0.51 and a 200-day moving average price of $0.51.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Biopharmx Corp (BPMX) Will Announce Quarterly Sales of $20,000.00” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/10/analysts-expect-biopharmx-corp-bpmx-will-announce-quarterly-sales-of-20000-00-updated-updated-updated.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related stocks with our FREE daily email newsletter.